scispace - formally typeset
G

Gabriele Ihorst

Researcher at University of Freiburg

Publications -  203
Citations -  7053

Gabriele Ihorst is an academic researcher from University of Freiburg. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 41, co-authored 184 publications receiving 5858 citations. Previous affiliations of Gabriele Ihorst include University Medical Center Freiburg.

Papers
More filters
Journal ArticleDOI

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology

TL;DR: A literature analysis on trends regarding changes in the incidence, geographic distribution, and etiologic factors of non-Hodgkin’s lymphoma finds that a male predominance throughout all age groups is apparent, and increases in high-grade NHL and extranodal disease are predominant.
Journal ArticleDOI

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

TL;DR: Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Journal ArticleDOI

Comparison of pseudobinaural hearing to real binaural hearing rehabilitation after cochlear implantation in patients with unilateral deafness and tinnitus.

TL;DR: The results in patients with unilateral deafness suggest that cochlear implantation improves hearing abilities in people with single-sided deafness and is superior to the alternative treatment options.
Journal ArticleDOI

Croup is associated with the novel coronavirus NL63.

TL;DR: HCoV-NL63 infections occur frequently in young children with LRTI and show a strong association with croup, suggesting a causal relationship.
Journal ArticleDOI

High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma

TL;DR: Sequential systemic methotrexate and AraC and thiotepa followed by HDT plus ASCT and hyperfractionated WBRT is very effective with little toxicity as initial therapy for PCNSL.